Dr. Dana Lambert left hospital pharmacy in 2013 to study cannabinoid pharmacology, learned plant medicine from indigenous elders, and bet her career on the whole plant. A new Oxford-published study shows two cannabinoids most dispensary customers have never asked for, CBC and CBG, can make silver work 64 times harder against MRSA, E. coli and Pseudomonas.
“I asked the cannabis plant (yes, I asked the plant itself, as recommended by the elders) to create better medicine.”
That is not a sentence you expect from a woman with a PhD in pharmaceutical sciences who runs a biotech company. Dr. Dana Lambert wrote it herself, in a personal essay published earlier this year. She meant it literally.
The contradiction is the point.
From the bedside to the lab
Lambert grew up on Vancouver Island, started a business degree at the University of British Columbia at 17, then transferred to pharmaceutical sciences when she realized she cared more about the chemistry of medicine than the business of it. She graduated as a licensed pharmacist in 2010 and went to work in hospitals. The job lasted two and a half years.
“I saw firsthand at patients’ bedsides the suffering, and too often, the mortality, caused by cancer, treatment-resistant infections, non-healing wounds, and chronic pain,” she wrote. “My job was to optimize drug therapy for patients, but all too often, the available treatments fell short.”
She left clinical pharmacy in 2013 and went back to UBC for a PhD in cannabinoid pharmacology. During her training she had also studied with indigenous elders on Vancouver Island and in Central America. One teaching stayed with her.
A woman with esophageal cancer who had failed chemotherapy with paclitaxel, a drug derived from Pacific yew bark, was reportedly cured after drinking tea prepared by an elder using the whole bark. The single isolated compound failed. The whole plant worked.
That observation became Lambert’s working thesis: pharmaceuticals routinely fail to capture the medicinal range of the plants they come from, because they isolate one active ingredient and discard everything else.
Cannabis is the plant for which this thesis was built.
“I asked the cannabis plant (yes, I asked the plant itself, as recommended by the elders) to create better medicine.”
Dr. Dana Lambert
What Oxford published
On April 21, the Journal of Applied Microbiology, an Oxford University Press journal, published a study from Lambert’s company, Andira Pharmaceuticals, and the University of British Columbia. The findings are not subtle.
The researchers tested silver, an antimicrobial used in wound care and medical devices for centuries, against three of the bacteria responsible for the worst hospital-acquired infections: MRSA, E. coli and Pseudomonas aeruginosa. Silver alone is losing the fight, both to bacterial resistance and to its own toxicity at higher doses.
When the researchers added two cannabinoids most dispensary customers have never asked for, cannabichromene (CBC) and cannabigerol (CBG), the math changed. The combination cut the silver dose required by up to 64-fold. It converted weak bacterial growth inhibition into rapid killing. It cleared bacterial biofilms, which are present in over 60% of diabetic ulcers and which most antibiotics can’t touch.
What the Oxford study found
Silver combined with CBC and CBG vs. silver alone, against the bacteria responsible for the worst hospital-acquired infections.
64×
Reduction in silver dose required
0
MRSA resistance after 20-day exposure
3
Superbugs killed: MRSA, E. coli, Pseudomonas
>90%
MRSA biofilms cleared by the combination
Source: Dietrich et al., Journal of Applied Microbiology, Oxford University Press, 2026.
“This work identifies a practical way to revitalize an existing antimicrobial that is already widely used in healthcare,” Lambert said in a statement.
The most consequential finding came from a 20-day resistance test. The researchers ran the silver-CBC-CBG combination side by side against fusidic acid, a standard antibiotic, exposing MRSA to both compounds at sub-lethal doses every day for three weeks. By day two, fusidic acid had already lost most of its punch. The combination held flat for the full passage.
Resistance development over 20 days
MRSA exposed to silver-CBC-CBG combination vs. fusidic acid (control).
Silver + CBC + CBG (no resistance)
Fusidic acid (resistance emerged)
Source: Dietrich et al., Journal of Applied Microbiology, Oxford University Press, 2026. Higher fold-MIC shift means more resistance.
A vacuum nobody else is filling
The framing of the paper is medical. The implication is bigger.
Antimicrobial resistance is one of the World Health Organization’s top global health threats. Big Pharma has largely walked away from antibiotic development because the unit economics don’t work. Hospital-acquired infections cost the United States an estimated $28 to $45 billion a year, according to the Oxford paper.
Into that vacuum walked a Vancouver pharmacist with a PhD, a research team at UBC and a thesis she did not invent in a lab. She inherited it from a woman who beat esophageal cancer with tea.
Andira is now preparing two parallel Phase 1/2a clinical trials of the silver-CBC-CBG combination, branded as Silvanex Topical, for surgical wounds and chronic diabetic ulcers. Both are scheduled to begin in Q4 2026, with FDA Fast Track and QIDP applications to follow.
“I’m probably the furthest thing from an academic scientist you’ll ever meet.”
Dr. Dana Lambert
Lambert is candid about how she got here. “I’m probably the furthest thing from an academic scientist you’ll ever meet,” she said in an earlier interview with this reporter. “I did it because I wanted to learn how to develop drugs and get involved in early-stage research and drug discovery.”
She has also been candid about the philosophical scaffolding. In her own essay, she wrote that her belief in the medicine she is developing rests on “the understanding that both human and plant intelligence came together to create them.”
Most pharma CEOs would never put that sentence in writing.
For thirty years the cannabis conversation in the United States has been a fight over THC. The medical horizon got handed to CBD, mostly through wellness products with thin clinical backing. Meanwhile CBC and CBG, the cannabinoids the industry treats as filler in full-spectrum products, are quietly the ones showing up in Oxford journals.
Lambert spent fifteen years preparing for this moment. The plant, in her telling, was not a metaphor.
The minor cannabinoids were never minor.
